Total amount: € 0,00
Official Journal of the , the International Union of Phlebology and the
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,899
Online ISSN 1827-1839
Allaert F. A. 1, 2
1 Health Claim Medical Evaluation ESC, Dijon, France;
2 Cen Nutriment, Dijon, France
Aim: The aim of the study was to examine the effect on blood pressure of replacing NaCl sea salt by NaCl + chitosan 3% (Symbiosal) during the diet and lifestyle improvement period prescribed to patients before any antihypertensive treatment.
Methods: This was a double-blind, randomized, crossover, controlled clinical trial of Symbiosal (NaCl + chitosan 3%) versus NaCl over two eight-week periods on 40 patients with mild hypertension for which they had never previously been treated.
Results: The effect of Symbiosal appeared as early as the first period of the crossover trial showing a reduction in systolic blood pressure (SBP) from 149.2±4.9 mmHg to 136.1±9.5 mmHg in patients on Symbiosal (reduction of 13.1±10.8 mmHg) versus a reduction from 149.7±4.6 mmHg to 142.9±7.7 mmHg in patients on traditional NaCl (reduction of 6.8±7.5 mmHg) (P=0.0404). Similar results were observed for diastolic blood pressure (DBP) with a reduction of 11.2±7.4 mmHg versus 7±8 mmHg (P=0.0560). HBP was brought under control (SBP ≤140 and DBP ≤90) in 76.2% (16/21) versus 36.8% (7/19)% of patients, respectively (P=0.0119). The crossover analysis confirmed the results showing Symbosial effects for both SBP (P=0.0156) and DBP (P=0.0285).
Conclusion: Replacing traditional NaCl by Symbiosal in conjunction with recommended alterations to lifestyle and diet significantly contributes to better control of hypertension and may postpone the prescription of antihypertensive drugs.